

DR. REDDY'S LABORATORIES LTD.

8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500034. Telangana, India.

CONTACT	
INVESTOR RELATIONS	MEDIA RELATIONS
RICHA PERIWAL RICHAPERIWAL@DRREDDYS.COM	PRIYA K PRIYAK@DRREDDYS.COM
ARJUN THAKKAR IGRC.SIL@SANOFI.COM	VINIFER GANDHI VINIFER.GANDHI@SANOFI.COM

Dr. Reddy's and Sanofi Healthcare India Private Limited expand partnership to launch Beyfortus® (nirsevimab), a novel drug for preventing Respiratory Syncytial Virus in India

- *Beyfortus® (nirsevimab) is the first monoclonal antibody approved to protect all infants born during or entering their 1st Respiratory Syncytial Virus (RSV) season*
- *Dr. Reddy's receives exclusive rights from Sanofi to promote and distribute Beyfortus® in India*
- *This announcement follows Dr. Reddy's successful exclusive distribution partnership with Sanofi for their vaccine brands in India last year*

Hyderabad, India; April 28, 2025 – On the occasion of World Immunization Week, Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as "Dr. Reddy's"), a global pharmaceutical company, expands its strategic partnership with Sanofi Healthcare India Private Limited ("SHIPL") to introduce a novel drug, Beyfortus® (nirsevimab), in India. Beyfortus® contains the monoclonal antibody, nirsevimab, in a prefilled injection used for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season. It is also administered in children up to 24 months of age, who remain vulnerable to severe RSV disease through their second RSV season.

Under the arrangement, Dr. Reddy's will have exclusive rights from SHIPL to promote and distribute Beyfortus® (nirsevimab) in India. This announcement follows Dr. Reddy's successful exclusive distribution partnership with Sanofi for their portfolio of vaccines in India last year. Dr. Reddy's is expected to launch Beyfortus® in India in the second quarter of the current fiscal year.

RSV is a highly contagious virus that can lead to serious respiratory illness for infantsⁱ. Two out of three infants are infected with RSV during their first year of life and almost all children are infected by their second birthdayⁱⁱ. In addition to being the most common cause of LRTD such as bronchiolitis and pneumonia in infantsⁱⁱⁱ, RSV is also a leading cause of hospitalization in infants worldwide, with most hospitalizations occurring in healthy infants born at term^{iv,v,vii}. In 2019, there were approximately 33 million

ⁱ U.S. Centers for Disease Control and Prevention. RSV in Infants and Young Children. <https://www.cdc.gov/rsv/high-risk/infants-youngchildren.html>. Accessed August 2023.

ⁱⁱ Walsh EE. Respiratory Syncytial Virus Infection: An Illness for All Ages. *Clinics in Chest Medicine*. 2017;38(1):29-36. <https://doi.org/10.1016/j.ccm.2016.11.010>.

ⁱⁱⁱ R K. Respiratory Syncytial Virus Vaccines. Plotkin SA, Orenstein WA, Offitt PA, Edwards KM, eds Plotkin's Vaccines 7th ed Philadelphia. 2018;7th ed. Philadelphia:943-9.

^{iv} Leader S, Kohlase K. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. *The Pediatric infectious disease journal*. 2002;21(7):629-32.

^v McLaurin KK, Farr AM, Wade SW, Diakun DR, Stewart DL. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants. *Journal of Perinatology: official journal of the California Perinatal Association*. 2016;36(11):990-6.

^{vi} Rha B, et al. Respiratory Syncytial Virus-Associated Hospitalizations Among Young Children: 2015-2016. *Pediatrics*. 2020;146:e20193611.

^{vii} Arriola CS, et al. Estimated Burden of Community-Onset Respiratory Syncytial Virus-Associated Hospitalizations Among Children Aged <2 Years in the United States, 2014-15. *J Pediatric Infect Dis Soc*. 2020;9:587-595.

cases of acute lower respiratory infections globally, leading to more than 3 million hospitalizations, and it was estimated that there were 26,300 in-hospital deaths of children younger than 5 years^{viii}.

Nitya Padmanabhan, Head of Sanofi Vaccines (India) said, *“Bringing Beyfortus® to India is a pivotal step in our mission to protect every child from immunization preventable diseases like RSV. In India, where the disease burden is significant and early protection is critical, this collaboration with Dr. Reddy’s enables us to reach parents and healthcare providers with an innovative solution. Together, we are advancing equitable access to immunization and improving preventive care for numerous children in India.”*

M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy’s, said, *“We are happy to extend our partnership with Sanofi in India - this time for a novel drug to address the RSV burden among newborns and infants in India. This partnership highlights our continued efforts to become the ‘partner of choice’ in bringing novel, innovative and trusted drugs to patients. Beyfortus® enables the access of healthcare professionals and parents to an improved drug in the prevention of RSV. Additionally, the launch of Beyfortus® will help us strengthen our immunization portfolio in India.”*

Beyfortus® has been approved for use in the European Union, the U.S., China, Japan, and many other countries around the world. In India, Beyfortus® received its marketing authorization approval in June last year from the Central Drugs Standard Control Organization (CDSCO).

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.

Sanofi in India

Present in India for nearly seven decades, we have earned the trust of our customers and stakeholders for our commitment to promoting health. As we chase the miracles of science to improve people’s lives, we continue to engage across the entire health spectrum from prevention with vaccines to wellness, treatment, patient support & capacity building. Our India Charitable Access Program (InCAP) is the country’s longest running humanitarian program providing free treatment to people afflicted with Lysosomal Storage Disorders. We conduct clinical trials in India, so India can have quicker access to the latest from our global pipeline. Our world-class manufacturing site in Goa produces for people in India and 60+ other countries. We have located one of our four global talent hubs in Hyderabad, India, from where wide range of services are provided globally. Recognized by the ‘Top® Employers Institute’ – a global authority that honours excellence in people practices – for 6 years in a row (since 2019), our local entities include Sanofi India Limited (SIL – listed entity) and Sanofi Healthcare India Pvt. Ltd. (SHIPL). Visit us at www.sanofi.in and www.sanofiindia.td.com, or connect with us on [LinkedIn](https://www.linkedin.com/company/sanofi) and [Twitter](https://twitter.com/sanofi).

About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team across the world is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on Euronext: SAN and NASDAQ: SN

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our

^{viii} Li Y, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399:92047–64.

public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2024. The company assumes no obligation to update any information contained herein.